Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 5:19 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001933414-26-000056
| Line item | Year Ended / December 31, 2025 | Year Ended / December 31, 2024 |
|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (814,738) | (373,445) |
| Maturities of marketable securities | 425,000 | 488,500 |
| Purchases of property and equipment | (15) | (96) |
| Net cash provided by (used in) investing activities | (389,753) | 114,959 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock in September 2025 public offering, net of offering costs | 269,883 | — |
| Proceeds from issuance of common stock in March 2025 public offering, net of offering costs | 188,880 | — |
Item 8. F-1 Item 8. Financial Statements and Supplementary Data
FAQ
- What is Mineralys Therapeutics, Inc.'s capex?
- Mineralys Therapeutics, Inc. (MLYS) reported capex of $15K in Q4 2025.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Mineralys Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude